HER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancers
Filipa C. Lynce, O. Martínez-Sáez, Benjamín Walbaum, F. Brasó-Maristany et autres
BACKGROUND: The HER2DX assay predicts long-term prognosis and pathologic complete response (pCR) in patients with early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer receiving neoadjuvant systemic therapy but has not been evaluated in inflammatory breast cancer (IBC). PATIENTS AND METHODS: …
us, cl, es (code pays fourni par la source)